Botanix Pharmaceuticals' Q3 Results Beat Estimates, Says Euroz Hartleys

MT Newswires Live

Yesterday

Botanix Pharmaceuticals (ASX:BOT) fiscal third quarter results beat Euroz Hartleys' estimates with the fifth consecutive quarter of prescription growth, according to a Thursday Euroz Hartleys note.

Total prescriptions increased 5% quarter-on-quarter to 26,684, slightly above Euroz Hartleys' estimates of 26,500. and gross-to-net yield declined quarter-on-quarter from 24% to 18%, in line with the research firm's expectations.

The company's current AU$60 million enterprise value does not fully reflect the AU$34.5 million of inventory held on the balance sheet, the research firm added.

The research firm believes that Botanix's Sofdra has the makings of a category leader in hyperhidrosis, a dermatology condition, and added that consistent prescription growth alone, or the addition of a new product to its platform, can potentially re-rate the stock "materially higher."

Euroz Hartkeys has a buy rating on Botanix Pharmaceuticals with a price target of AU$0.25.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2632262692"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2632262692\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2632262692?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 14:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632262692","market":"sh","top_or_hot":-1,"title":"Botanix Pharmaceuticals' Q3 Results Beat Estimates, Says Euroz Hartleys","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/BOT.AU\">Botanix Pharmaceuticals</a> (ASX:BOT) fiscal third quarter results beat <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys' estimates with the fifth consecutive quarter of prescription growth, according to a Thursday Euroz Hartleys note.</p><p>Total prescriptions increased 5% quarter-on-quarter to 26,684, slightly above Euroz Hartleys' estimates of 26,500. and gross-to-net yield declined quarter-on-quarter from 24% to 18%, in line with the research firm's expectations.</p><p>The company's current AU$60 million enterprise value does not fully reflect the AU$34.5 million of inventory held on the balance sheet, the research firm added.</p><p>The research firm believes that Botanix's Sofdra has the makings of a category leader in hyperhidrosis, a dermatology condition, and added that consistent prescription growth alone, or the addition of a new product to its platform, can potentially re-rate the stock \"materially higher.\"</p><p>Euroz Hartkeys has a buy rating on Botanix Pharmaceuticals with a price target of AU$0.25.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Botanix Pharmaceuticals' Q3 Results Beat Estimates, Says Euroz Hartleys</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBotanix Pharmaceuticals' Q3 Results Beat Estimates, Says Euroz Hartleys\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-01 14:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/BOT.AU\">Botanix Pharmaceuticals</a> (ASX:BOT) fiscal third quarter results beat <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys' estimates with the fifth consecutive quarter of prescription growth, according to a Thursday Euroz Hartleys note.</p><p>Total prescriptions increased 5% quarter-on-quarter to 26,684, slightly above Euroz Hartleys' estimates of 26,500. and gross-to-net yield declined quarter-on-quarter from 24% to 18%, in line with the research firm's expectations.</p><p>The company's current AU$60 million enterprise value does not fully reflect the AU$34.5 million of inventory held on the balance sheet, the research firm added.</p><p>The research firm believes that Botanix's Sofdra has the makings of a category leader in hyperhidrosis, a dermatology condition, and added that consistent prescription growth alone, or the addition of a new product to its platform, can potentially re-rate the stock \"materially higher.\"</p><p>Euroz Hartkeys has a buy rating on Botanix Pharmaceuticals with a price target of AU$0.25.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7502","symbol_name":"大麻概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2632262692","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2632262692","pubTimestamp":1777616044,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Botanix Pharmaceuticals  fiscal third quarter results beat Euroz Hartleys' estimates with the fifth consecutive quarter of prescription growth, according to a Thursday Euroz Hartleys note.Total prescriptions increased 5% quarter-on-quarter to 26,684, slightly above Euroz Hartleys' estimates of 26,500. and gross-to-net yield declined quarter-on-quarter from 24% to 18%, in line with the research firm's expectations.The company's current AU$60 million enterprise value does not fully reflect the AU$34.5 million of inventory held on the balance sheet, the research firm added.The research firm believes that Botanix's Sofdra has the makings of a category leader in hyperhidrosis, a dermatology condition, and added that consistent prescription growth alone, or the addition of a new product to its platform, can potentially re-rate the stock \"materially higher.\"Euroz Hartkeys has a buy rating on Botanix Pharmaceuticals with a price target of AU$0.25.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7502":"大麻概念","BK7508":"医药生物股","BK7096":"制药","BOT.AU":"BOTANIX PHARMACEUTICALS LTD"},"translate_title":"Euroz Hartleys表示，Botanix Pharmaceuticals第三季度业绩超出预期","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BOT.AU":1},"content_text":"Botanix Pharmaceuticals (ASX:BOT) fiscal third quarter results beat Euroz Hartleys' estimates with the fifth consecutive quarter of prescription growth, according to a Thursday Euroz Hartleys note.Total prescriptions increased 5% quarter-on-quarter to 26,684, slightly above Euroz Hartleys' estimates of 26,500. and gross-to-net yield declined quarter-on-quarter from 24% to 18%, in line with the research firm's expectations.The company's current AU$60 million enterprise value does not fully reflect the AU$34.5 million of inventory held on the balance sheet, the research firm added.The research firm believes that Botanix's Sofdra has the makings of a category leader in hyperhidrosis, a dermatology condition, and added that consistent prescription growth alone, or the addition of a new product to its platform, can potentially re-rate the stock \"materially higher.\"Euroz Hartkeys has a buy rating on Botanix Pharmaceuticals with a price target of AU$0.25.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}